|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Meador CB and Hata AN: Acquired resistance
to targeted therapies in NSCLC: Updates and evolving insights.
Pharmacol Ther. 210(107522)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to The 2015 World Health
Organization classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Scheffler M, Bos M, Gardizi M, König K,
Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F,
et al: PIK3CA mutations in non-small cell lung cancer (NSCLC):
Genetic heterogeneity, prognostic impact and incidence of prior
malignancies. Oncotarget. 20:1315–1326. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhou X, Wang X, Zhu H, Gu G, Zhan Y, Liu C
and Sun G: PI3K inhibition sensitizes EGFR wild-type NSCLC cell
lines to erlotinib chemotherapy. Exp Ther Med. 21(9)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hanker AB, Kaklamani V and Arteaga CL:
Challenges for the clinical development of PI3K inhibitors:
Strategies to improve their impact in solid tumors. Cancer Discov.
9:482–491. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Basnet R, Gong GQ, Li C and Wang MW: Serum
and glucocorticoid inducible protein kinases (SGKs): A potential
target for cancer intervention. Acta Pharm Sin B. 8:767–771.
2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Talarico C, Dattilo V, D'Antona L, Menniti
M, Bianco C, Ortuso F, Alcaro S, Schenone S, Perrotti N and Amato
R: SGK1, the new player in the game of resistance: Chemo-radio
molecular target and strategy for inhibition. Cell Physiol Biochem.
39:1863–1876. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang Z, Xu Q, Song C, Mi B, Zhang H, Kang
H, Liu H, Sun Y, Wang J, Lei Z, et al: Serum- and
glucocorticoid-inducible kinase 1 is essential for
osteoclastogenesis and promotes breast cancer bone metastasis. Mol
Cancer Ther. 19:650–660. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lee LYW, Woolley C, Starkey T, Biswas S,
Mirshahi T, Bardella C, Segditsas S, Irshad S and Tomlinson I:
Serum- and glucocorticoid-induced kinase Sgk1 directly promotes the
differentiation of colorectal cancer cells and restrains
metastasis. Clin Cancer Res. 25:629–640. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Toska E, Castel P, Chhangawala S,
Arruabarrena-Aristorena A, Chan C, Hristidis VC, Cocco E, Sallaku
M, Xu G, Park J, et al: PI3K inhibition activates SGK1 via a
feedback loop to promote chromatin-based regulation of ER-dependent
gene expression. Cell Rep. 27:294–306.e5. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Castel P, Ellis H, Bago R, Toska E, Razavi
P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, et
al: PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation
and confers resistance to PI3Kα inhibition. Cancer Cell.
30:229–242. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Parra ER, Villalobos P, Mino B and
Rodriguez-Canales J: Comparison of different antibody clones for
immunohistochemistry detection of programmed cell death ligand 1
(PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol
Morphol. 26:83–93. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Juneja VR, McGuire KA, Manguso RT, LaFleur
MW, Collins N, Haining WN, Freeman GJ and Sharpe AH: PD-L1 on tumor
cells is sufficient for immune evasion in immunogenic tumors and
inhibits CD8 T cell cytotoxicity. J Exp Med. 214:895–904.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dantoing E, Piton N, Salaün M, Thiberville
L and Guisier F: Anti-PD1/PD-L1 immunotherapy for non-small cell
lung cancer with actionable oncogenic driver mutations. Int J Mol
Sci. 22(6288)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Adorisio S, Cannarile L, Delfino DV and
Ayroldi E: Glucocorticoid and PD-1 cross-talk: Does the immune
system become confused? Cells. 10(2333)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang L, Huang F, Mei J, Wang X, Zhang Q,
Wang H, Xi M and You Z: Posttranscriptional control of PD-L1
expression by 17β-estradiol via PI3K/Akt signaling pathway in
ERα-positive cancer cell lines. Int J Gynecol Cancer. 27:196–205.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hydbring P, Malumbres M and Sicinski P:
Non-canonical functions of cell cycle cyclins and cyclin-dependent
kinases. Nat Rev Mol Cell Biol. 17:280–292. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
McCubrey JA, Steelman LS, Franklin RA,
Abrams SL, Chappell WH, Wong EWT, Lehmann BD, Terrian DM, Basecke
J, Stivala F, et al: Targeting the RAF/MEK/ERK, PI3K/AKT and p53
pathways in hematopoietic drug resistance. Adv Enzyme Regul.
47:64–103. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Won M, Park KA, Byun HS, Kim YR, Choi BL,
Hong JH, Park J, Seok JH, Lee YH, Cho CH, et al: Protein kinase
SGK1 enhances MEK/ERK complex formation through the phosphorylation
of ERK2: Implication for the positive regulatory role of SGK1 on
the ERK function during liver regeneration. J Hepatol. 51:67–76.
2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tenbaum SP, Ordóñez-Morán P, Puig I,
Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert
JD, Mendizabal L, et al: β-catenin confers resistance to PI3K and
AKT inhibitors and subverts FOXO3a to promote metastasis in colon
cancer. Nat Med. 18:892–901. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Jiang L, Zhang J, Xu Y, Xu H and Wang M:
Treating non-small cell lung cancer by targeting the PI3K signaling
pathway. Chin Med J (Engl). 135:1272–1284. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mishra R, Patel H, Alanazi S, Kilroy MK
and Garrett JT: PI3K inhibitors in cancer: Clinical implications
and adverse effects. Int J Mol Sci. 22(3464)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sherk AB, Frigo DE, Schnackenberg CG, Bray
JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK,
Kazmin D, et al: Development of a small-molecule serum- and
glucocorticoid-regulated kinase-1 antagonist and its evaluation as
a prostate cancer therapeutic. Cancer Res. 68:7475–7483.
2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tolcher AW, Peng W and Calvo E: Rational
approaches for combination therapy strategies targeting the MAP
kinase pathway in solid tumors. Mol Cancer Ther. 17:3–16.
2018.PubMed/NCBI View Article : Google Scholar
|
